Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first oral therapy

- PMLiVE

Government wants Prof David Haslam to be new NICE chair

He would take over from Prof Sir Michael Rawlins in April

- PMLiVE

Pfizer set for negative NICE decision on Inlyta

Institute's draft guidance doesn't recommend drug for advanced kidney cancer

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

- PMLiVE

Roche wins company of the year at PMEA 2012

Also picks up team of the year at awards to recognise excellence in the pharmaceutical market

- PMLiVE

NICE backs Servier’s heart failure drug Procoralan

But recommendation includes a number of restrictions that limit NHS use of the drug

Roche - Basel

Roche offers compromise in Tamiflu data debate

Comes as EMA holds workshop on clinical trial data and transparency

- PMLiVE

Astellas seeks FDA approval for personalised Tarceva in lung cancer

Application supported by Roche's EGFR companion diagnostic test

- PMLiVE

Roche’s Avastin cuts progression of aggressive brain cancer

Supports potential new indication for oncology medicine

Roche, social media and patients – part 2

Patient groups talk about their use of social media and the challenges they face

- PMLiVE

EFPIA says “indiscriminate” data transparency could be harmful

Comments come as European Parliament prepares to discuss clinical trial overhaul

Roche, social media and patients – part 1

UK pharma company talks about its digital patient group summit Share+

- PMLiVE

Researcher calls for Roche boycott over missing Tamiflu data

Nordic Cochrane Centre's Peter Gøtzsche also wants European governments to sue the pharma company for withholding data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links